Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Neostigmine

Related Products

Hot Products

Basic Information Post buying leads Suppliers
Name

Neostigmine

EINECS N/A
CAS No. 59-99-4 Density 1.0718 (rough estimate)
PSA 29.54000 LogP 1.94370
Solubility N/A Melting Point N/A
Formula C12H19N2O2 Boiling Point 364.59°C (rough estimate)
Molecular Weight 223.295 Flash Point N/A
Transport Information N/A Appearance N/A
Safety A deadly poison by ingestion, subcutaneous, intramuscular, intravenous, and intraperitoneal routes. When heated to decomposition it emits toxic fumes of NOx and NH3. See also CARBAMATES. Risk Codes N/A
Molecular Structure Molecular Structure of 59-99-4 (Neostigmine) Hazard Symbols N/A
Synonyms

Prostigmin;Eustigmin;[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;Neostigmine;Juvastigmin;Eustigmine;Prostigmine;Neostigminum;Vagostigmine;Intrastigmina;Syntostigmine;

 

Neostigmine Chemical Properties

Chemistry informtion about Neostigmine (CAS NO.59-99-4) is:
IUPAC Name: [3-(Dimethylcarbamoyloxy)Phenyl]-Trimethylazanium
Synonyms: 3-[[(Dimethylamino)Carbonyl]Oxy]-N,N,N-Trimethylbenzenaminium ; Eustigmin ; Eustigmine ; Vagostigmine
MF: C12H19N2O2+
MW: 223.291460 g/mol
Following is the molecular structure of Neostigmine (CAS NO.59-99-4) is:

Neostigmine History

Neostigmine was first synthesized by Aeschlimann and Reinert in 1931.It is made by first reacting 3-dimethylaminophenol with N-dimethylcarbamoyl chloride, which forms a dimethylcarbamate. Next, that product is alkylated using dimethylsulfate, which forms neostigmine.

Neostigmine Uses

Neostigmine (CAS NO.59-99-4) is used to improve muscle tone in people with myasthenia gravis and routinely, in anesthesia at the end of an operation, to reverse the effects of non-depolarizing muscle relaxants such as rocuronium and vecuronium. It can also be used for urinary retention resulting from general anaesthesia and to treat curariform drug toxicity. Another indication for use is the Ogilvie syndrome which is a pseudoobstruction of the colon in critically ill patients. Historically, it has been used as a test for early pregnancy. In a non-pregnant female whose menstrual period is delayed, administration of neostigmine can provoke menstrual bleeding. Modern tests which rely on detecting hCG in urine have rendered this application obsolete.Though one of only two treatments available for myasthenia gravis this drug is no longer available to anyone using the Medicare Part D program.

Neostigmine Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LDLo subcutaneous 769ug/kg (0.769mg/kg) behavioral: muscle contraction or spasticity) gastrointestinal: changes in structure or function of salivary glands gastrointestinal: ulceration or bleeding from large intestine Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 5, Pg. 184, 1946.
mouse LD50 intraperitoneal 380ug/kg (0.38mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 192, Pg. 88, 1971.
mouse LD50 intravenous 160ug/kg (0.16mg/kg)   International Journal of Neuropharmacology. Vol. 8, Pg. 131, 1969.
mouse LD50 oral 12340ug/kg (12.34mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 117, Pg. 75, 1956.
mouse LD50 subcutaneous 280ug/kg (0.28mg/kg) behavioral: tremor behavioral: convulsions or effect on seizure threshold lungs, thorax, or respiration: cyanosis Journal of Pharmacy and Pharmacology. Vol. 34, Pg. 603, 1982.
rabbit LD50 intramuscular 340ug/kg (0.34mg/kg)   Drug and Chemical Toxicology. Vol. 3, Pg. 319, 1980.
rabbit LD50 intravenous 250ug/kg (0.25mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 452, 1948.
rabbit LD50 subcutaneous 500ug/kg (0.5mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 452, 1948.
rat LD50 intravenous 225ug/kg (0.225mg/kg)
peripheral nerve and sensation: flaccid paralysis without anesthesia (usually neuromuscular blockage) sense organs and special senses: chromodacyrorrea: eye lungs, thorax, or respiration: structural or functional change in trachea or bronchi
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 101, Pg. 205, 1955.

Neostigmine Safety Profile

A deadly poison by ingestion, subcutaneous, intramuscular, intravenous, and intraperitoneal routes. When heated to decomposition it emits toxic fumes of NOx and NH3. See also CARBAMATES.

Neostigmine Specification

Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor.It is available under several trade names such as Prostigmin and Vagostigmin. By interfering with the breakdown of acetylcholine, it indirectly stimulates both nicotinic and muscarinic receptors. Unlike physostigmine, Neostigmine has a quarternary nitrogen; hence, it is more polar and does not enter the CNS. its effect on skeletal muscle is greater than that of physostigmine, and it can stimulate contractility before it paralyzes. Neostigmine has short duration of action, usually thirty minutes to two hours. Neostigmine binds to the anionic site of cholinesterase. The drug blocks the active site of acetylcholinesterase so the enzyme can no longer break down the acetylcholine molecules before they reach the postsynaptic membrane receptors. This allows for the threshold to be reached so a new impulse can be triggered in the next neuron. In myasthenia gravis there are too few acetylcholine receptors so with the acetylcholinesterase blocked, acetylcholine can bind to the few receptors and trigger a muscular contraction. It can induce generic occular side effects including: headache, brow pain, blurred vision, phacodinesis,pericorneal injection, congestive iritis, various allergic reactions, and rarely, retinal detachment and it will cause slowing of the heart rate (bradycardia), for this reason it is usually given along with a parasympatholytic drug such as atropine or glycopyrrolate.Gastrointestial symptoms occur earliest after ingestion and include anorexia, nausea and vomiting, abdominal cramps and diarrhea.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 59-99-4